STAAR Surgical (NASDAQ:STAA) Major Shareholder Acquires $1,296,840.00 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 53,500 shares of the stock in a transaction dated Monday, December 16th. The shares were bought at an average cost of $24.24 per share, for a total transaction of $1,296,840.00. Following the acquisition, the insider now owns 10,821,931 shares in the company, valued at $262,323,607.44. The trade was a 0.50 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The stock was bought at an average price of $24.33 per share, for a total transaction of $559,590.00.

STAAR Surgical Trading Down 4.6 %

Shares of STAA opened at $24.26 on Thursday. The stock has a 50 day simple moving average of $28.43 and a 200-day simple moving average of $34.63. The stock has a market cap of $1.20 billion, a PE ratio of 55.14 and a beta of 0.59. STAAR Surgical has a 1 year low of $23.72 and a 1 year high of $52.68.

Institutional Investors Weigh In On STAAR Surgical

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC boosted its position in STAAR Surgical by 173.5% in the second quarter. SG Americas Securities LLC now owns 9,038 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 5,733 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in STAAR Surgical by 3.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock worth $540,000 after acquiring an additional 418 shares during the last quarter. Louisiana State Employees Retirement System raised its position in STAAR Surgical by 2.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 24,700 shares of the medical instruments supplier’s stock valued at $1,176,000 after purchasing an additional 500 shares during the last quarter. Slow Capital Inc. raised its holdings in shares of STAAR Surgical by 3.1% in the second quarter. Slow Capital Inc. now owns 67,649 shares of the medical instruments supplier’s stock valued at $3,221,000 after buying an additional 2,003 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in STAAR Surgical by 1.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 405,222 shares of the medical instruments supplier’s stock worth $19,293,000 after buying an additional 5,712 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on STAA shares. Canaccord Genuity Group reduced their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a report on Monday, December 9th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Stifel Nicolaus lowered their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 26th. Finally, Stephens raised STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical presently has an average rating of “Hold” and an average price target of $42.83.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.